What do systematic reviews say?

INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) vs MAINTENANCE THERAPY

It is very uncertain whether INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).

• Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
  RR 2.12 [0.7, 6.37]
  3 studies · 257 participants
  Very low

Comparison 1: Individual CBT‐based psychotherapy vs TAU or another comparator

Comparison 1.1: Individual‐based CBT‐based psychotherapy showed no clear difference in repetition of SH at post‐intervention compared with TAU or another comparator (low certainty).

• Psychosocial interventions for self‐harm in adults 2021 · Cochrane Headline outcomes only
  OR 0.35 [0.12, 1.02]
  4 studies · 238 participants
  Low

Homeopathic medicinal products (individualised treatment) vs placebo or usual care

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 369 participants
  Low

Homeopathic medicinal products (individualised treatment) vs placebo or usual care

Homeopathic medicinal products (individualised treatment) showed no clear difference in recurrence of ARTI compared with placebo or usual care (moderate certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 1.31 [0.64, 2.7]
  1 study · 199 participants
  Moderate

Homeopathic medicinal products (individualised treatment) vs placebo or usual care

Homeopathic medicinal products (individualised treatment) showed no clear difference in days off work for parents compared with placebo or usual care (moderate certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 1.46 [0.83, 2.55]
  1 study · 199 participants
  Moderate

Homeopathic medicinal products (individualised treatment) vs placebo or usual care

Homeopathic medicinal products (individualised treatment) showed no clear difference in need for antibiotics compared with placebo or usual care (low certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 0.79 [0.35, 1.76]
  2 studies · 369 participants
  Low

Homeopathic medicinal products (individualised treatment) vs placebo or usual care

Homeopathic medicinal products (individualised treatment) showed no clear difference in adverse events compared with placebo or usual care (moderate certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 2.51 [0.75, 8.42]
  1 study · 199 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 62 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 61 participants
  Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1132 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 946 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 944 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 944 participants
  Low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1057 participants
  Moderate